MedTrace Logo

Appropriate Opioid Quantities for Acute Pain - Pharmacist Study

NCT04484610 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2022-07-20

No results posted yet for this study

Summary

Prescription opioids contribute to opioid related deaths, overdose and addiction. Unused prescribed opioids are not routinely being stored or disposed of appropriately and their availability is associated with harms. Maximum daily doses prescribed are higher than that recommended in a significant number of patients. This study is designed to help have appropriate doses and quantities of opioids dispensed for the treatment of short-term pain. Rather than targeting prescribing, this study targets the dispensing process by training community pharmacists to assess the appropriateness and safety of opioid prescriptions for short-term pain and to work with patients to partially fill prescriptions if the quantities prescribed are deemed excessive. Patient education tools were developed to help promote understanding of opioid safety, including the use of appropriate quantities, safe storage and safe disposal. Pharmacists in five randomly selected regions in Ontario, Canada are targeted for the eLearning intervention. The primary study outcome is the quantities dispensed for initial opioid prescriptions for short-term pain in the intervention regions compared to ten control regions.

Conditions

  • Opioid Use
  • Acute Pain

Interventions

DRUG

Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain

Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.

Sponsors & Collaborators

  • Institute of Safe Medication Practices Canada

    collaborator UNKNOWN

  • North York General Hospital

    collaborator OTHER

  • The Royal Ottawa Mental Health Centre

    collaborator OTHER

  • Ontario Drug Policy Research Network

    collaborator UNKNOWN

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Beth Sproule, PharmD · Centre for Addiction and Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2022-02-21
Completion
2022-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04484610 on ClinicalTrials.gov